Roivant Sciences (ROIV) Scheduled to Post Earnings on Tuesday

Roivant Sciences (NASDAQ:ROIV) is scheduled to release its earnings data before the market opens on Tuesday, November 12th. Analysts expect Roivant Sciences to post earnings of ($0.21) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.33. Roivant Sciences had a negative return on equity of 17.23% and a net margin of 2,991.75%. The company had revenue of $55.10 million for the quarter, compared to analyst estimates of $30.72 million. During the same period in the previous year, the company posted ($0.38) earnings per share. The company’s quarterly revenue was up 155.1% compared to the same quarter last year. On average, analysts expect Roivant Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Roivant Sciences Stock Down 0.1 %

Roivant Sciences stock traded down $0.01 during midday trading on Tuesday, reaching $11.52. The stock had a trading volume of 916,917 shares, compared to its average volume of 5,847,779. The stock has a market capitalization of $8.52 billion, a P/E ratio of 2.07 and a beta of 1.24. The firm’s fifty day simple moving average is $11.81 and its 200-day simple moving average is $11.27. The company has a debt-to-equity ratio of 0.05, a quick ratio of 27.91 and a current ratio of 27.91. Roivant Sciences has a 1-year low of $8.47 and a 1-year high of $13.06.

Insider Buying and Selling

In other news, COO Eric Venker sold 100,000 shares of the company’s stock in a transaction on Monday, October 21st. The stock was sold at an average price of $11.65, for a total transaction of $1,165,000.00. Following the completion of the sale, the chief operating officer now directly owns 617,470 shares in the company, valued at approximately $7,193,525.50. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the company’s stock in a transaction on Monday, October 21st. The stock was sold at an average price of $11.65, for a total transaction of $1,165,000.00. Following the completion of the sale, the chief operating officer now directly owns 617,470 shares in the company, valued at $7,193,525.50. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Financial Lp Qvt sold 876,000 shares of Roivant Sciences stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $11.82, for a total value of $10,354,320.00. Following the completion of the transaction, the director now owns 22,179,358 shares in the company, valued at approximately $262,160,011.56. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,577,309 shares of company stock valued at $42,151,184 over the last 90 days. 7.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

ROIV has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research report on Thursday, September 19th. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. Piper Sandler lifted their target price on Roivant Sciences from $20.00 to $22.00 and gave the company an “overweight” rating in a research report on Wednesday, July 10th. Finally, Bank of America increased their price target on Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research report on Wednesday, September 11th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $17.39.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.